The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...

The 60.8% response rate regardless of PD-L1 expression (TPS 0-100%) represents a substantial improvement compared to historical control of 48.0%. 1 The relative outperformance is particularly strong ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

Detailed price information for Bioinvent International Ab (BOVNF) from The Globe and Mail including charting and trades.

Efti plus Keytruda and chemotherapy achieved a 60.8% ORR and 90.2% DCR in advanced NSCLC patients. The combination therapy showed improved ORR across all PD-L1 expression levels compared to historical ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...